Grifols (GRF SM) Q3 2026 (EUR): Revenue 2.04bln (exp. 1.97bln); Net income 162mln; Adj. EBITDA 538mln (exp. 515.8mln)

Grifols (GRF SM) Q3 2026 (EUR): Revenue 2.04bln (exp. 1.97bln); Net income 162mln; Adj. EBITDA 538mln (exp. 515.8mln)

Grifols printed revenue of EUR 2.04bln against EUR 1.97bln expected and adjusted EBITDA of EUR 538mln against EUR 515.8mln expected, with net income at EUR 162mln, so the headline is a clean top-line and profit beat on the consensus carried in the wire. For a leveraged plasma-derived therapies issuer, the established sequence is that the first move is mechanical on the beat, then the stock re-trades on the quality of the beat: plasma collection volumes, immunoglobulin and albumin pricing, mix, and working capital separate an operational quarter from a working-capital or one-off flattered one. The relevant transmission channel is not the quarterly print itself but the credibility of the deleveraging path, since equity has historically been a proxy for the slope of net debt to EBITDA and for refinancing risk in euro credit, with the CDS and senior spreads often confirming or rejecting the equity message before the equity settles. The distinction that matters is between a beat that raises guidance and one that merely pulls forward volume, because the former compresses the equity risk premium while the latter mainly reshapes intra-year estimates. The tells are the full-year outlook, commentary on collection capacity versus fractionation demand, pricing discipline in core plasma proteins, cash conversion, and any language on asset sales, equity issuance, or covenant headroom. Given the issuer’s prior association with leverage scrutiny and governance sensitivity, confirmation from cash flow and balance-sheet detail carries more weight than the headline margin alone.